Express News | CRISPR Therapeutics AG : Leerink Partners Cuts Target Price to $60 From $65
Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $57
Palantir, Crispr, and Other Stocks Cathie Wood Thinks Could Emerge Strong From a Recession -- Barrons.com
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Cathie Wood Thinks These Firms Could Emerge Strong From a Recession
Express News | Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target
70107480 OP : I think its best to hold on to our cash, it may go Green from time to time, but there will be more Red in the days and months to come, i think.